Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor

Ophthalmologica

Volumn 226, Issue 3, 2011, Pages 145-150

  Inoue, Maiko ^a   Kobayakawa, Shinichiro ^b   Sotozono, Chie ^c   Komori, Hideki ^c   Tanaka, Kumiko ^b   Suda, Yuzo ^d   Matsushima, Hiroyuki ^d   Kinoshita, Shigeru ^c   Senoo, Tadashi ^d   Tochikubo, Tetsuo ^b   Kadonosono, Kazuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti vascular endothelial growth factor; Endophthalmitis; Intravitreal injection

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; OFLOXACIN; PEGAPTANIB; RANIBIZUMAB; VANCOMYCIN; VASCULOTROPIN ANTIBODY;

ARTICLE; BACTERIUM CULTURE; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; HUMAN; JAPAN; STREPTOCOCCUS ORALIS; VITRECTOMY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; AQUEOUS HUMOR; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; EYE INFECTIONS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; JAPAN; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS ORALIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 80053122333     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000329863     Document Type: Article

References (32)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 363-372, e365.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816. (Pubitemid 40051904)
4. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005. (Pubitemid 44973218)
5. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, DAmico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD: A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757. (Pubitemid 41400011)
6. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-1712. (Pubitemid 44442451)
7. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27: 419-425. (Pubitemid 46624280)
8. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL: Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115:e47-e54.
9. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T: Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116: 362.
10. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M: Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882.
11. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S: Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28: 1395-1399.
12. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM: Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009; 29: 601-605.
13. Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, Ooto S, Sasahara M, Iwama D, Yoshimura N: Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010; 30: 485-490.
14. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, Oyagi T, Sawada K: Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010; 117: 512-516.
15. Bakri SJ, Larson TA, Edwards AO: Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 779-781.
16. Ness T, Feltgen N, Agostini H, Bohringer D, Lubrich B: Toxic vitreitis outbreak after intravitreal injection. Retina 2010; 30: 332-338.
17. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H: Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009; 23: 2187-2193.
18. Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Pina Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA: Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 2010; 4: 519-524.
19. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F: Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23: 240-242. (Pubitemid 46986604)
20. Jonas JB, Spandau UH, Schlichtenbrede F: Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 2008; 22: 590-591. (Pubitemid 351560425)
21. Fung AE, Rosenfeld PJ, Reichel E: The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349. (Pubitemid 44702055)
22. Klein KS, Walsh MK, Hassan TS, Halperin LS, Castellarin AA, Roth D, Driscoll S, Prenner JL: Endophthalmitis after anti-VEGF injections. Ophthalmology 2009; 116: 1225.
23. Shimada H, Nakashizuka H, Hattori T, Mori R, Mizutani Y, Yuzawa M: Incidence of endophthalmitis after 20-and 25-gauge vitrectomy: causes and prevention. Ophthalmology 2008; 115: 2215-2220.
24. Hu AY, Bourges JL, Shah SP, Gupta A, Gonzales CR, Oliver SC, Schwartz SD: Endophthalmitis after pars plana vitrectomy: a 20-and 25-gauge comparison. Ophthalmology 2009; 116: 1360-1365.
25. Oshima Y, Kadonosono K, Yamaji H, Inoue M, Yoshida M, Kimura H, Ohji M, Shiraga F, Hamasaki T: Multicenter survey with a systematic overview of acute-onset endophthalmitis after transconjunctival microincision vitrectomy surgery. Am J Ophthalmol 2010; 150: 716-725.
26. Ta CN: Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004; 24: 699-705. (Pubitemid 39391759)
27. Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR: Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laserranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009; 127: 1581-1583.
28. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, DAmico DJ, Flynn HW Jr, Grillone LR, Hutcherson S, Liebmann JM, OBrien TP, Scott IU, Spaide RF, Ta C, Trese MT: Evolving guidelines for intravitreous injections. Retina 2004; 24:S3-S19. (Pubitemid 39391785)
29. Schwartz SG, Flynn HW, Scott IU: End ophthalmitis after intravitreal injections. Expert Opin Pharmacother 2009; 10: 2119-2126.
30. Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S: Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008; 115: 1911-1915.
31. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
32. Roth DB, Flynn HW Jr: Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008; 146: 346-347